Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs
19 déc. 2024 08h00 HE
|
Assembly Biosciences, Inc.
—Assembly Bio to receive approximately $20.1 million equity investment and $10 million in accelerated funding under the collaboration, extending cash runway to mid-2026— —Additional equity...
Cannara Biotech Inc. Reports Q4 and Fiscal Year 2024 Results: Achieves Record Sales Growth and Operating Cash Flow, Solidifying Leadership in Canada's Cannabis Market
25 nov. 2024 09h30 HE
|
Cannara Biotech (Québec) Inc.
Cannara Biotech reports record FY2024 revenue of $82.2M (+43%), strong Q4 growth, 3.2% national market share, and plans for expanded production.
Cornish Metals Releases Unaudited Financial Statements and Management’s Discussion and Analysis for the Nine Months Ended 30 September 2024
21 nov. 2024 02h00 HE
|
Cornish Metals Inc.
Cornish Metals released its unaudited financial statements and management, discussion and analysis (“MD&A”) for the nine months ended September 30, 2024.
Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates
12 nov. 2024 16h05 HE
|
Fractyl Health, Inc.
REMAIN-1 weight maintenance pivotal study enrollment progressing rapidly; mid-point data analysis expected in Q2 2025
Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates
07 nov. 2024 16h05 HE
|
Assembly Biosciences, Inc.
Positive Phase 1a interim data released for ABI-5366, a long-acting HSV helicase-primase inhibitor candidate for recurrent genital herpes, supporting potential for once-weekly and once-monthly oral...
Q3 update: Novonesis delivers strong Q3 results and now expects full-year organic sales growth at the upper end of 7-8%
07 nov. 2024 02h02 HE
|
Novonesis (Novozymes A/S)
Following increasing demand in the first nine months of the 2024 financial year, Novonesis delivers 9% organic sales growth with a strong 11% organic sales growth in the third quarter. The strong...
Fractyl Health to Report Third Quarter 2024 Financial Results and Provide Business Updates on November 12, 2024
29 oct. 2024 07h00 HE
|
Fractyl Health, Inc.
BURLINGTON, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that treat root causes...
Orezone Provides Notice of Q3-2024 Results and Conference Call
28 oct. 2024 14h03 HE
|
Orezone Gold Corporation
VANCOUVER, British Columbia, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Orezone Gold Corporation (TSX: ORE, OTCQX: ORZCF) (“Orezone”) will announce its third quarter 2024 results on November 5, 2024, after...
Fractyl Health to Present Compelling Weight Maintenance Data from both Revita® and Rejuva® Platforms at ObesityWeek® 2024
28 oct. 2024 07h00 HE
|
Fractyl Health, Inc.
Fractyl Health to Present Compelling Weight Maintenance Data from both Revita® and Rejuva® Platforms at ObesityWeek® 2024
CSX Corporation Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm’s Investigation
21 oct. 2024 16h50 HE
|
Block & Leviton LLP
Block & Leviton is investigation CSX Corp. for potential securities law violations. Investors who lost money in CSX should contact the firm to learn more.